open access
Plerixafor for patients who fail cytokine-or chemotherapy-based stem cell mobilization: Results of a prospective study by the Polish Lymphoma Research Group (PLRG)
Affiliations- Centrum Onkologii – Instytut im. M. Skłodowskiej- Curie Oddział w Gliwicach, Gliwice
- Klinika Chorób Wewnętrznych, Nefrologii i Dializoterapii, Wojskowy Instytut Medyczny, 04-141, ul. Szaserów 128, Warszawa, ul. Szaserów 128, 04-141, Poland
- 4Konsultant w dziedzinie angiologii województwa małopolskiego, Oddział Angiologii i Kardiologii, Szpital Uniwersytecki w Krakowie;
- Katedra i Klinika Endokrynologii i Diabetologii Wieku Rozwojowego, Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu, Poland
- Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie, Lublin
- Instytut Hematologii i Transfuzjologii w Warszawie
- First Department of Cardiology, Medical University of Gdansk, Gdansk I Klinika Kardiologii, Gdański Uniwersytet Medyczny, Gdańsk
- Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznań
- I Katedra i Klinika Kardiologii, Warszawski Uniwersytet Medyczny
- Oddział Torakochirurgii Świętokrzyskie Centrum Onkologii
open access
Abstract
Autologous hematopoietic stem cell transplantation (autoHSCT) requires collection of sufficient number of hematopoietic stem cells. The goal of this study was to evaluate efficacy of plerixafor used in patients with lymphoid malignancies failing conventional stem cell mobilization.
This was a prospective, non-interventional study. All consecutive patients (n = 109) treated with plerixafor in 11 centers were reported. The drug was used either in case of previous mobilization failure (n = 67) or interventionally, in case of insufficient CD34 cell output during current mobilization (n = 42). Successful mobilization was defined as resulting in collection of ≥ 2 × 10 CD34 cells/kg for single autoHSCT or ≥ 4 × 10 CD34 cells/kg for double procedure.
The overall rate of successful mobilization was 55% (55% for single and 56% for double autoHSCT). The median total number of collected CD34 cells/kg was 2.4 (range, 0-11.5) for patients intended for a single transplantation while 4.0 (0.6-16.9) for double procedure. The number of circulating CD34 cells increased after the use of plerixafor regardless of baseline values. The median fold increase was 3.3 (0.3-155). Data from this observational study confirm high efficacy of plerixafor used in routine clinical practice as salvage for patients with lymphoid malignancies failing conventional stem cell mobilization.
Abstract
Autologous hematopoietic stem cell transplantation (autoHSCT) requires collection of sufficient number of hematopoietic stem cells. The goal of this study was to evaluate efficacy of plerixafor used in patients with lymphoid malignancies failing conventional stem cell mobilization.
This was a prospective, non-interventional study. All consecutive patients (n = 109) treated with plerixafor in 11 centers were reported. The drug was used either in case of previous mobilization failure (n = 67) or interventionally, in case of insufficient CD34 cell output during current mobilization (n = 42). Successful mobilization was defined as resulting in collection of ≥ 2 × 10 CD34 cells/kg for single autoHSCT or ≥ 4 × 10 CD34 cells/kg for double procedure.
The overall rate of successful mobilization was 55% (55% for single and 56% for double autoHSCT). The median total number of collected CD34 cells/kg was 2.4 (range, 0-11.5) for patients intended for a single transplantation while 4.0 (0.6-16.9) for double procedure. The number of circulating CD34 cells increased after the use of plerixafor regardless of baseline values. The median fold increase was 3.3 (0.3-155). Data from this observational study confirm high efficacy of plerixafor used in routine clinical practice as salvage for patients with lymphoid malignancies failing conventional stem cell mobilization.
Keywords
plerixafor; stem cell mobilization; multiple myeloma; Hodgkin lymphoma; non-Hodgkin lymphoma
About this articleTitle
Plerixafor for patients who fail cytokine-or chemotherapy-based stem cell mobilization: Results of a prospective study by the Polish Lymphoma Research Group (PLRG)
Journal
Issue
Pages
234-239
Published online
2018-12-31
Page views
202
Article views/downloads
233
DOI
10.2478/ahp-2018-0027
Bibliographic record
Acta Haematol Pol 2018;49(4):234-239.
Keywords
plerixafor
stem cell mobilization
multiple myeloma
Hodgkin lymphoma
non-Hodgkin lymphoma
Authors
Sebastian Giebel
Sylwia Oborska
Joanna Romejko-Jarosinska
Jarosław Dybko
Joanna Mańko
Joanna Sawczuk-Chabin
Agata Szymańska
Wojciech Legieć
Anna Czyż
Magdalena Maruszak
Maria Saduś-Wojciechowska
Joanna Drozd-Sokołowska
Paweł Steckiewicz
Anna Ejduk
Ewa Paszkiewicz-Kozik
Tomasz Ogórka
Michał Osowiecki
Łukasz Targoński
Michał Taszner